Corporate ActionMay 8, 2026, 05:12 PM
Akari Therapeutics Plans Public Offering of ADSs & Warrants
AI Summary
Akari Therapeutics Plc filed an S-1 registration statement for a public offering of up to 1,139,818 American Depositary Shares (ADSs) and accompanying Series H and Series I Warrants. The offering, on a best-efforts basis with no minimum, has an assumed combined public offering price of $6.58 per ADS and warrants, aiming for estimated maximum net proceeds of approximately $6.7 million. The company, a preclinical oncology firm with no product revenue, intends to use the proceeds for research and development, working capital, and general corporate purposes, noting existing cash is sufficient only through mid-2027 without these funds.
Key Highlights
- Offering up to 1,139,818 ADSs, Series H Warrants, and Series I Warrants.
- Assumed combined public offering price of $6.58 per ADS and accompanying warrants.
- Estimated maximum net proceeds of approximately $6.7 million from the offering.
- Offering is on a best-efforts basis with no minimum amount required.
- Pre-Funded Warrants available for purchasers exceeding 4.99% or 9.99% ownership.
- Series H Warrants expire in 5 years; Series I Warrants expire in 12 months.
- Company completed a 1-for-40 reverse split of ADSs on March 31, 2026.
- Net proceeds to fund research and development, working capital, and general corporate purposes.
Price Impact
More from AKTX